Monday, October 26, 2026

ON Semiconductor Guides AI Data Center Revenue to Double in 2026, Sparking 60% Stock Surge

ON Semiconductor projected its AI data center revenue will double year-over-year in 2026 following a Q1 earnings beat. The stock climbed 60.1% over three months on the guidance. The signal points to widening outperformance for AI-focused chip names versus the broader semiconductor sector.

LM Salvado
LM Salvado

May 20, 2026

ON Semiconductor Guides AI Data Center Revenue to Double in 2026, Sparking 60% Stock Surge
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

ON Semiconductor guided its AI data center revenue to double year-over-year in 2026, a forecast that sent the stock up 60.1% over the three months following its Q1 earnings beat.1

The guidance is one of the clearest demand signals yet from the chip supply chain. AI infrastructure buildout is accelerating, and component suppliers with direct data center exposure are pulling ahead of general semiconductor peers.

ON Semi's positioning matters. The company supplies power management and sensing chips used in AI server infrastructure. A revenue doubling projection in that segment reflects not just current orders but committed purchasing pipelines from hyperscalers.1

For traders, the divergence thesis is straightforward: AI-specific semiconductor exposure is outperforming the broader chip index. The test is whether AI data center segments at companies like ON Semi and Nvidia outpace the general semiconductor sector by more than 20% on revenue growth through Q3 2026.1

Macro conditions complicate the picture. The 10-Year US Treasury benchmark moved from 4.31 to 5, signaling tighter financial conditions.1 Rising rates typically compress valuations across growth equities. The exception has been high-growth AI names, where earnings acceleration has overridden multiple compression.

Convertible debt markets are also shifting. ON Semi's 2.50% Convertible Senior Notes saw a notable parameter drop, suggesting restructuring activity in AI-adjacent balance sheets.1 Companies are repositioning capital structures ahead of what they expect to be a sustained growth cycle.

The broader read for semiconductor investors: earnings guidance from AI-adjacent suppliers is now a leading indicator for the sector. When a company with direct hyperscaler exposure doubles its AI revenue forecast, the signal carries weight for the entire supply chain — from power delivery to advanced packaging to memory.

Q2 and Q3 results will test whether the guidance holds. If AI data center revenue tracks the doubling trajectory, expect further rotation into AI-specific chip names and continued underperformance from commodity semiconductor exposure.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com